Literature DB >> 27383019

Detection of the Cholera Toxin-binding Activity of κ-Casein Macropeptide and Optimization of Its Production by the Response Surface Methodology.

S Oh1, R W Worobo1, B C Kim2, S Rheem3, S Kim2.   

Abstract

The cholera toxin (CT)-binding activity of purified κ-casein macropeptide (CMP) from bovine κ-casein was detected. In addition, a statistical model was developed to optimize the production of CMP. CMP was prepared by chymosin hydrolysis of κ-casein and a subsequent 3% trichloroacetic acid treatment. CMP was further fractionated in an ion-exchange column by FPLC. CT binding activity was eluted at 0.18 M NaCl and was a single 8.9 kDa peptide without tyrosine and arginine residues. The CT binding activity was rapidly lost by a carbohydrase treatment. The conditions for CMP production with chymosin were optimized by using the response surface methodology (RSM). The estimated optimum levels of the factors were as follows: reaction temperature, 38.5°C; pH, 6.44; and time, 35.9 min. A validation experiment was performed in which CMP was prepared under the predicted parameters, and it was ascertained that the estimated optimum conditions gave better production of CMP than any other conditions.

Entities:  

Keywords:  cholera toxin; response surface methodology; κ-casein macropeptide

Year:  2000        PMID: 27383019     DOI: 10.1271/bbb.64.516

Source DB:  PubMed          Journal:  Biosci Biotechnol Biochem        ISSN: 0916-8451            Impact factor:   2.043


  2 in total

1.  Effects of casein glycomacropeptide supplementation on growth performance, intestinal morphology, intestinal barrier permeability and inflammatory responses in Escherichia coli K88 challenged piglets.

Authors:  Yili Rong; Zeqing Lu; Haiwen Zhang; Lin Zhang; Deguang Song; Yizhen Wang
Journal:  Anim Nutr       Date:  2015-06-03

2.  Administration of Extensive Hydrolysates From Caseins and Lactobacillus rhamnosus GG Probiotic Does Not Prevent Cow's Milk Proteins Allergy in a Mouse Model.

Authors:  Karine Adel-Patient; Marine Guinot; Blanche Guillon; Hervé Bernard; Amina Chikhi; Stéphane Hazebrouck; Christophe Junot
Journal:  Front Immunol       Date:  2020-09-11       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.